J07BA02 - Encephalitis, Japanese, Inactivated, Whole Virus |
Propably not porphyrinogenic |
PNP |
Important Information
In general, vaccines are regarded safe since such substance is not suspected to give an up-regulation of the heme biosynthesis as a direct effect. However, some vaccines can cause a reaction with high fever persisting over days as a side effect. It is possible that this side effect can trigger an acute porphyric attack in the same way as infections are known to. Vigilance is therefore motivated when administrating a vaccine known to cause reactions with fever.
Side effects
Fever is reported as a common side effect (very common in children under 18) of the Japanese encephalitis vaccine, and it is possible that this side effect can trigger an acute porphyric attack in the same way as infections are known to.
Nausea and vomiting are also reported as common adverse reactions, and may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Based on the pharmacokinetics of the Japanese encephalitis, inactivated, whole virus vaccine there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated Japanese encephalitis virus strain SA14-14-2.
Therapeutic characteristics
The Japanese encephalitis vaccine is indicated for active immunization against Japanese encephalitis in adults, adolescents, children and infants aged 2 months and older.
It is administered as two intramuscular injections, normally given one month apart.
Side effects:
Metabolism and pharmacokinetics
The encephalitis vaccine is not metabolized by the Cytochrome P450 system
References
- Government bodies
- Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Ixiaro. (Last edition: 26.05. 2016). #1873
Similar drugs
© NAPOS 2024